Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2010 Financial Results
Date:11/4/2010

NEW YORK, Nov. 4, 2010 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease (the "Company"), today announced its results for the third quarter ended September 30, 2010.

At September 30, 2010, the Company had cash, cash equivalents, interest receivable and investment securities of $34.4 million, as compared to $31.7 million at June 30, 2010, and $35.9 million at December 31, 2009.  During the third quarter, the Company received approximately $5.7 million in net proceeds from the exercise of the remaining warrants from the Company's September 2009 registered direct offering.

The net loss for the third quarter ended September 30, 2010 was $5.8 million, or $0.10 per diluted share, compared to net income of $0.6 million, or $0.01 per diluted share, for the third quarter in 2009, representing a change in net (loss) income of $6.4 million.  The three months ended September 30, 2009 included $3.5 million in other revenue, related to the settlement of a dispute with the former licensor of Sulonex (sulodexide), in July 2009, over issues arising from the terminated license agreement.  The three months ended September 30, 2010 included a $2.2 million increase in research and development expenses related to KRX-0401 (perifosine) and Zerenex as compared to the comparable period last year, primarily related to the Company's ongoing Phase 3 clinical development programs.  The net loss for the third quarter ended September 30, 2010, included $0.6 million of non-cash compensation expense related to equity incentive grants.

The net loss for the nine months ended September 30, 2010 was $15.0 million, or $0.26 per diluted share
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ... the "Dental Consumables Market - Global Industry ... - 2018" report to their offering. ... ) Dental consumables are products which are ... impairments, for tooth restoration and in treatment of ...
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading ... company, awarded several new IT value-added reseller (VAR) ... hospital organizations with IT goods and services at ... agreements, as well as value-added services such as ... New Novation agreements were awarded to ...
(Date:1/15/2014)... DUBLIN , January 15, 2014 ... that it has waived the Office of Fair Trading (OFT) ... the outstanding shares of ViroPharma Incorporated (NASDAQ: VPHM).   ... no longer conditional on OFT approval, and Shire expects to ... currently scheduled expiration time, subject to the satisfaction of all ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... Amarin Corporation plc (Nasdaq: AMRN ... the Canaccord Genuity 5th Annual Cardiovascular, Diabetes & Obesity Conference ... will be held at the Nikko Hotel in San Francisco. ... be available at the following URL:   ...
... received 510(k) clearance from the U.S. Food and Drug ... spot scanning. Spot scanning is a proton therapy delivery ... the tumor by using thousands of small individual beamlets ... Intensity Modulated Proton Therapy (IMPT). XiO, Elekta,s ...
Cached Medicine Technology:Amarin to Present at Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference 2Elekta Receives FDA 510(k) Clearance for XiO Software to Plan Spot Scanning for Proton Therapy 2
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... history of snoring, apnea , , WEDNESDAY, June 11 (HealthDay News) ... a sleep-related breathing disorder, says a University of Virginia study. ... to 18 years, who were referred to a pediatric sleep ... an increased frequency of snoring. , The children,s neck size, ...
... been ruled out as source of contaminated tomatoes, they ... health officials said Wednesday they are zeroing in on ... contaminated tomatoes. , "The question is where specifically did ... for foods at the U.S. Food and Drug Administration ...
... Mayo Clinic research suggests unmarried women living in rural ... counterparts. This lower health status often includes greater instances ... study were recently published in the Journal of ... care physicians should take a proactive role in addressing ...
... Case Western Reserve University School of Medicine and Penn ... that reduces sterile inflammation within the cornea. Published in ... Biology, Dr. Eric Pearlman and Dr. Mark Kester ... delivered in nano-sized packages reduces corneal haze, corneal thickening ...
... of some NSAIDS, it could prevent buildup of plaque ... (HealthDay News) -- A class of drugs called gamma-secretase ... study suggests. , A hallmark of Alzheimer,s is so-called ... gamma-secretase modulators reduce the production of long pieces of ...
... Paris, France, Wednesday June 11th 2008: At least 50% ... state free of signs and symptoms) within 36 weeks ... in combination with tight control, according to results of ... Congress of the European League Against Rheumatism in Paris, ...
Cached Medicine News:Health News:Children's Neck Size Associated With Sleep Disorders 2Health News:U.S. Health Officials Closer to Origin of Salmonella Outbreak 2Health News:U.S. Health Officials Closer to Origin of Salmonella Outbreak 3Health News:U.S. Health Officials Closer to Origin of Salmonella Outbreak 4Health News:Mayo Clinic study reveals rural, unmarried women at higher risk for depression 2Health News:New Class of Drugs May Fight Alzheimer's 2Health News:New Class of Drugs May Fight Alzheimer's 3Health News:50 percent of recent onset RA patients become free of signs and symptoms within 36 weeks 2
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
This unit is the finest standalone handswitch bipolar unit available....
...
...
Medicine Products: